Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

640 ARTÍCULOS , VIENDO DEL 451 AL 465

Prediction of Alzheimer's disease with serum lipid levels in Asian individuals: a meta-analysis

Wu Y, Wang Z, Jia X, Zhang H, Zhang H, Li J, Zhang K.

Biomarkers. 2019 Jun;24(4):341-351. doi: 10.1080/1354750X.2019.1571633. Epub 2019 Feb 13.

M/EEG-Based Bio-Markers to Predict the MCI and Alzheimer's Disease: A Review From the ML Perspective

Yang S, Bornot JMS, Wong-Lin K, Prasad G.

IEEE Trans Biomed Eng. 2019 Oct;66(10):2924-2935. doi: 10.1109/TBME.2019.2898871. Epub 2019 Feb 12.

European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol

Solomon A, Kivipelto M, Molinuevo JL, Tom B, Ritchie CW; EPAD Consortium.

BMJ Open. 2019 Feb 19;8(12):e021017. doi: 10.1136/bmjopen-2017-021017.

Peripheral inflammatory biomarkers in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis

Su C, Zhao K, Xia H, Xu Y.

Psychogeriatrics. 2019 Jul;19(4):300-309. doi: 10.1111/psyg.12403. Epub 2019 Feb 20.

Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative

Sato K, Mano T, Ihara R, Suzuki K, Tomita N, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H, Iwatsubo T, Toda T, Iwata A; Alzheimer’s Disease Neuroimaging Initiative, and Japanese Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;68(2):777-788. doi: 10.3233/JAD-181115.

Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study

Scaricamazza E, Colonna I, Sancesario GM, Assogna F, Orfei MD, Franchini F, Sancesario G, Mercuri NB, Liguori C.

Neurol Sci. 2019 Jul;40(7):1377-1382. doi: 10.1007/s10072-019-03840-4. Epub 2019 Mar 22.

[Biomarkers of Alzheimer's disease in older and oldest old patients]

Lilamand M, Cognat E, Goutagny S, Hourregue C, Hugon J, Dumurgier J, Paquet C.

Geriatr Psychol Neuropsychiatr Vieil. 2019 Mar 1;17(1):65-72. doi: 10.1684/pnv.2019.0779.

Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial

Forlenza OV, Radanovic M, Talib LL, Gattaz WF.

Br J Psychiatry. 2019 Nov;215(5):668-674. doi: 10.1192/bjp.2019.76.

Evaluation of CD33 as a genetic risk factor for Alzheimer's disease

Estus S, Shaw BC, Devanney N, Katsumata Y, Press EE, Fardo DW.

Acta Neuropathol. 2019 Aug;138(2):187-199. doi: 10.1007/s00401-019-02000-4. Epub 2019 Apr 4.

Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer's Disease

Mustapic M, Tran J, Craft S, Kapogiannis D.

J Alzheimers Dis. 2019;69(2):489-498. doi: 10.3233/JAD-180578.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker

Peña-Bautista C, Roca M, Hervás D, Cuevas A, López-Cuevas R, Vento M, Baquero M, García-Blanco A, Cháfer-Pericás C.

J Proteomics. 2019 May 30;200:144-152. doi: 10.1016/j.jprot.2019.04.008. Epub 2019 Apr 9.

Plasmalogens and Alzheimer's disease: a review

Su XQ, Wang J, Sinclair AJ.

Lipids Health Dis. 2019 Apr 16;18(1):100. doi: 10.1186/s12944-019-1044-1.

Inflammatory biomarkers in Alzheimer's disease plasma

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium; Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau

Lafirdeen ASM, Cognat E, Sabia S, Hourregue C, Lilamand M, Dugravot A, Bouaziz-Amar E, Laplanche JL, Hugon J, Singh-Manoux A, Paquet C, Dumurgier J.

PLoS One. 2019 May 14;14(5):e0217026. doi: 10.1371/journal.pone.0217026. eCollection 2019.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias